Atezolizumab
- Generic Name
- Atezolizumab
- Brand Names
- Tecentriq
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1380723-44-3
- Unique Ingredient Identifier
- 52CMI0WC3Y
- Background
Atezolizumab is a humanized monoclonal antibody used to prevent the interaction of PD-L1 and PD-1, removing inhibition of immune responses seen in some cancers. This medication is reserved for patients whose tumors express PD-L1, cannot receive platinum-based chemotherapy, or whose tumors do not respond to platinum-based chemotherapy. Atezolizumab was granted FDA approval on 18 October 2016. In November 2022, the manufacturer (Genentech) voluntarily withdrew the use of atezolizumab for the treatment of urothelial carcinoma, previously approved under the FDA's Accelerated Approval Program. The rest of atezolizumab indications remain unaffected.
- Indication
Atezolizumab has approved indications for the following conditions:
Non-Small Cell Lung Cancer (NSCLC)
Small Cell Lung Cancer (SCLC)
Hepatocellular Carcinoma (HCC)
Melanoma
Alveolar Soft Part Sarcoma (ASPS)
- Associated Conditions
- Metastatic Alveolar Soft Part Sarcoma, Metastatic Hepatocellular Carcinoma, Metastatic Melanoma, Metastatic Non-Small Cell Lung Cancer, Metastatic Non-squamous Non Small Cell Lung Cancer, Non-Small Cell Lung Carcinoma, Nonsmall Cell Lung Cancer, Stage II, Small Cell Lung Cancer (SCLC), Stage IIIA Non Small Cell Lung Cancer, Triple-Negative Breast Cancer, Unresectable Alveolar Soft Part Sarcoma, Unresectable Hepatocellular Carcinoma (HCC), Unresectable Melanoma
- Associated Therapies
- -
A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer
- Conditions
- Interventions
- Drug: CapecitabineDrug: AtezolizumabDrug: Ribociclib (dose #1)Drug: Inavolisib (dose #2)Drug: AbemaciclibDrug: Trastuzumab DeruxtecanDrug: IpatasertibDrug: Sacituzumab GovitecanDrug: FulvestrantDrug: Ribociclib (dose #2)Drug: Inavolisib (dose #1)Drug: SGN-LIV1ADrug: Chemotherapy (Gemcitabine + Carboplatin or Eribulin)Drug: TocilizumabDrug: BevacizumabDrug: LetrozoleDrug: Nab-PaclitaxelDrug: InavolisibDrug: Selicrelumab
- First Posted Date
- 2018-02-06
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 580
- Registration Number
- NCT03424005
- Locations
- 🇺🇸
City of Hope, Duarte, California, United States
🇺🇸University of California San Diego Medical Center; Moores Cancer Center, La Jolla, California, United States
🇺🇸Stanford Cancer Institute, Stanford, California, United States
Atezolizumab, Rituximab, Gemcitabine and Oxaliplatin in Patients With Relapsed or Refractory DLBCL Not Suitable for High-dose Therapy
- First Posted Date
- 2018-02-05
- Last Posted Date
- 2022-08-22
- Target Recruit Count
- 53
- Registration Number
- NCT03422523
- Locations
- 🇬🇧
The Christie NHS Foundation Trust, Manchester, United Kingdom
Study of Atezolizumab + FLOT vs. FLOT Alone in Patients With GC/GEJ and High Immune Responsiveness
- Conditions
- Interventions
- First Posted Date
- 2018-02-05
- Last Posted Date
- 2023-08-14
- Target Recruit Count
- 674
- Registration Number
- NCT03421288
- Locations
- 🇩🇪
Krankenhaus Nordwest, Frankfurt, Germany
🇨🇭SAKK Coordinating Center, Bern, Switzerland
Atezolizumab + Pertuzumab + Trastuzumab In CNS Mets In BC
- Conditions
- Interventions
- First Posted Date
- 2018-01-31
- Last Posted Date
- 2024-07-05
- Lead Sponsor
- Nancy Lin, MD
- Target Recruit Count
- 19
- Registration Number
- NCT03417544
- Locations
- 🇺🇸
Northwestern University, Chicago, Illinois, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
A Study to Investigate The Effectiveness Of Atezolizumab In Patients With Inoperable Locally-Advanced Or Metastatic Urothelial Carcinoma Of The Urinary Tract (Announce)
- Conditions
- First Posted Date
- 2018-01-16
- Last Posted Date
- 2019-04-19
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 22
- Registration Number
- NCT03399643
- Locations
- 🇩🇪
Urologische Praxis Dr. Krieger, Chemnitz, Germany
🇩🇪Praxis Dr.med. Wolfgang Hölzer, Berlin, Germany
🇩🇪Zeisigwaldkliniken Bethanien, Chemnitz, Germany
Pre-operative Immunotherapy Combination Strategies in Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2018-01-10
- Last Posted Date
- 2024-06-18
- Lead Sponsor
- Queen Mary University of London
- Target Recruit Count
- 71
- Registration Number
- NCT03395899
- Locations
- 🇬🇧
Barts Health NHS Trust, London, United Kingdom
Atezolizumab With Neoadjuvant Chemotherapy for Patients With Newly-Diagnosed Advanced-Stage Ovarian Cancer
- Conditions
- Interventions
- First Posted Date
- 2018-01-09
- Last Posted Date
- 2021-08-12
- Lead Sponsor
- Duke University
- Target Recruit Count
- 18
- Registration Number
- NCT03394885
- Locations
- 🇺🇸
Duke Cancer Institute, Durham, North Carolina, United States
🇺🇸Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States
🇺🇸University of Virginia, Charlottesville, Virginia, United States
A Study of the Efficacy and Safety of Atezolizumab Plus Chemotherapy for Patients With Early Relapsing Recurrent Triple-Negative Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2017-12-13
- Last Posted Date
- 2024-11-08
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 595
- Registration Number
- NCT03371017
- Locations
- 🇩🇪
Klinikum Essen-Mitte Ev. Huyssens-Stiftung / Knappschafts GmbH; Klinik für Senologie / Brustzentrum, Essen, Germany
🇰🇷Samsung Medical Center, Seoul, Korea, Republic of
🇦🇷Fundación CENIT para la Investigación en Neurociencias, Buenos Aires, Argentina
A Study of Atezolizumab in Combination With an Immunotherapy Agent Investigated With or Without Anti-Cd20 Therapy in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2017-12-12
- Last Posted Date
- 2018-04-05
- Lead Sponsor
- Hoffmann-La Roche
- Registration Number
- NCT03369964
- Locations
- 🇺🇸
City of Hope Comprehensive Cancer Center, Duarte, California, United States
🇺🇸Tennessee Oncology, Nashville, Tennessee, United States
BEACON - ABC in Recurrent Platinum Resistant HGSOC
- Conditions
- Interventions
- First Posted Date
- 2017-12-06
- Last Posted Date
- 2023-08-07
- Lead Sponsor
- Peter MacCallum Cancer Centre, Australia
- Target Recruit Count
- 30
- Registration Number
- NCT03363867
- Locations
- 🇦🇺
Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.